Article summary
The Q3 2026 briefing, dated 2 October 2026, covers major developments from the prior quarter across psychedelic drug development, policy and regulation, science and academia. Founder and Editor Josh Hardman also looks ahead to the next quarter.
Continue to the original publication for the complete article.